1. Lake MA. What we know so far: COVID‑19 current clinical
knowledge and research. Clin Med (Lond) 2020;20:124‑7.
2. Wu F, Zhao S, Yu B, Chen Y, Wang W, Hu Y, et al. Complete
genome characterisation of a novel coronavirus associated with
severe human respiratory disease in Wuhan, China. bioRxiv 2020.
doi: 10.1101/2020.01.24.919183.
3. Zhou P, YangX, WangX, Hu B, Zhang L, ZhangW, et al. Discovery
of a novel coronavirus associated with the recent pneumonia
outbreak in humans and its potential bat origin. bioRxiv 2020.
doi: 10.1101/2020.01.22.914952.
4. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al.
Angiotensin‑converting enzyme 2 protects from severe acute
lung failure. Nature 2005;436:112‑6.
5. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB,
Tallant EA, et al. Effect of angiotensin‑converting enzyme
inhibition and angiotensin II receptor blockers on cardiac
angiotensin‑converting enzyme 2. Circulation 2005;111:2605‑10.
6. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID‑19 infection?
Lancet Respir Med 2020;8:e21.
7. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid
advice guideline for the diagnosis and treatment of 2019 novel
coronavirus (2019‑nCoV) infected pneumonia (standard version).
Mil Med Res 2020;7:4. doi: 10.1186/s40779‑020‑0233‑6.
8. Wösten‑van Asperen RM, Lutter R, Specht PA, Moll GN,
van Woensel JB, van der Loos CM, et al. Acute respiratory distress
syndrome leads to reduced ratio of ACE/ACE2 activities and
is prevented by angiotensin‑(1–7) or an angiotensin II receptor
antagonist. J Pathol 2011;225:618‑27.
9. Kumar S, Acharya S, Jain S, Shukla S, Talwar D, Shah D, et al. Role
of zinc and clinicopathological factors for COVID‑19‑associated
mucormycosis (CAM) in a rural hospital of central India:
A case‑control study. Cureus 2022;14:e22528. doi 10.7759/cureus.
22528.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet 2020;395:497‑506.
11. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical
characteristics of imported cases of COVID‑19 in Jiangsu province:
A multicenter descriptive study. Clin Infect Dis 2020;71:706‑12.
12. Tetlow S, Segiet‑Swiecicka A, O’Sullivan R, O’Halloran S, Kalb K,
Brathwaite‑Shirley C, Alger L, Ankuli A, Baig MS, Catmur F,
Chan T, Dudley D, Fisher J, Iqbal MU, Puczynska J, Wilkins R,
BygateR, Roberts P. ACE inhibitors, angiotensin receptor blockers
and endothelial injury in COVID‑19. J Intern Med. 2021 May;
289(5):688‑699. doi: 10.1111/joim. 13202.
13. BraudeP, CarterB, ShortR, Vilches‑MoragaA, VerduriA, PearceL,
et al. The influence of ACE inhibitors and ARBs on hospital length
of stay and survival in people with COVID‑19. Int J Cardiol Heart
Vasc 2020;31:100660. doi: 10.1016/j.ijcha. 2020.100660.
14. Senkal N, Meral R, Medetalibeyoglu A, Konyaoglu H, Kose M,
Tukek T. Association between chronic ACE inhibitor exposure
and decreased odds of severe disease in patients with COVID‑19.
Anatol J Cardiol 2020;24:21‑9.
15. Zhou F, Liu YM, Xie J, Li H, Lei F, Yang H, et al. Comparative
impacts of ACE (Angiotensin‑Converting Enzyme) inhibitors
versus angiotensin ii receptor blockers on the risk of COVID‑19
mortality. Hypertension 2020;76:e15‑7.
16. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A,
et al. Angiotensin‑converting enzyme inhibitors and angiotensin
II receptor blockers are not associated with severe COVID‑19
infection in a multi‑site UK acute hospital trust. Eur J Heart Fail
2020;22:967‑74.
17. Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R,
Mascitelli A, et al. Treatment with ACE inhibitors or ARBs
and risk of severe/lethal COVID‑19: A meta‑analysis. Heart
2020;106:1519‑24.
18. Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S,
Hulkoti V, et al. Interleukin 6 and its correlation with COVID‑19
in terms of outcomes in an intensive care unit of a rural hospital:
A cross‑sectional study. Indian J Crit Care Med 2022;26:39‑42.
19. Marashizadeh A, Sanati HR, Sadeghipour P, Peighambari MM,
Moosavi J, Shafe O, et al. Left ventricular end‑diastolic
pressure‑guided hydration for the prevention of contrast‑induced
acute kidney injury in patients with stable ischemic heart disease:
The LAKESIDE trial. Int Urol Nephrol 2019;51:1815‑22.
20. Sadeghipour P, Talasaz AH, Rashidi F, Sharif‑Kashani B,
Beigmohammadi MT, Farrokhpour M, et al. Effect of
Intermediate‑Dose vs Standard‑Dose Prophylactic Anticoagulation
on Thrombotic Events, Extracorporeal Membrane Oxygenation
Treatment, or Mortality Among Patients With COVID‑19
Admitted to the Intensive Care Unit: The INSPIRATION
Randomized Clinical Trial. JAMA. 2021 Apr 27;325(16):1620‑1630.
doi: 10.1001/jama. 2021.4152